Acute Ischemic Stroke Therapeutics Market 2024-2028
The acute ischemic stroke therapeutics market is forecasted to grow by USD 1742 mn during 2023-2028, accelerating at a CAGR of 6.1% during the forecast period. The report on the acute ischemic stroke therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of cardiovascular diseases, increasing adoption of direct oral anticoagulants, and increasing prevalence of sedentary lifestyles.
Technavio's acute ischemic stroke therapeutics market is segmented as below:
By Type
- Thrombolytics
- Anticoagulants
- Antiplatelets
- Antihypertensives
- Others
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the integrating genomic and clinical data through translational bioinformatics in acute ischemic stroke management as one of the prime reasons driving the acute ischemic stroke therapeutics market growth during the next few years. Also, advent of genomic medicine and strong pipeline of acute ischemic stroke therapeutics will lead to sizable demand in the market.
The report on the acute ischemic stroke therapeutics market covers the following areas:
- Acute Ischemic Stroke Therapeutics Market sizing
- Acute Ischemic Stroke Therapeutics Market forecast
- Acute Ischemic Stroke Therapeutics Market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading acute ischemic stroke therapeutics market vendors that include Amgen Inc., AstraZeneca Plc, Athersys Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., Johnson and Johnson Services Inc., Medtronic PLC, Merck and Co. Inc., NoNO Inc., Pfizer Inc., SanBio Co. Ltd., Sanofi SA, Stryker Corp., and Teva Pharmaceutical Industries Ltd.. Also, the acute ischemic stroke therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.